Linsey Haden, DO
Family Medicine · Lincoln, NENPI 1124256870
Payments from drug & device makers
Across 283 payments — averaging $15.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$419
- Pfizer$417
- Astellas Pharma US Inc$272
- Lilly USA, LLC$223
- Boehringer Ingelheim$192
- plus $943 from 30 others
What the payments were for
- Food & beverage$4,354100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 129 | $1,888 |
| Novo Nordisk | 25 | $419 |
| Pfizer | 27 | $417 |
| Astellas Pharma US Inc | 11 | $272 |
| Lilly USA, LLC | 16 | $223 |
| Boehringer Ingelheim | 14 | $192 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $97 |
| AstraZeneca | 7 | $90 |
| Bayer | 5 | $68 |
| Novartis | 3 | $47 |
| Merck | 3 | $46 |
| Sanofi Pasteur Inc. | 3 | $44 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $41 |
| Impulse Dynamics (USA) Inc. | 2 | $39 |
| Biohaven Pharmaceuticals, Inc. | 3 | $36 |
| Boston Scientific | 2 | $36 |
| Medtronic | 2 | $33 |
| Actelion Pharmaceuticals US, Inc. | 2 | $31 |
| Amgen | 2 | $28 |
| Abbott | 1 | $25 |
| Seqirus USA Inc | 1 | $25 |
| Mylan Specialty L.p. | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Exact Sciences | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Stryker | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| Kyowa Kirin, Inc. | 1 | $13 |
| Adlon Therapeutics L.p. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
How this compares
$4,354 in reported general payments places this provider in the 85th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 39 | $51,665 |
| OzempicSemaglutide | 26 | $44,738 |
| MounjaroTirzepatide | 25 | $41,011 |
| JanuviaSitagliptin Phosphate | 31 | $23,984 |
| XareltoRivaroxaban | 14 | $18,495 |
| VraylarCariprazine Hcl | 13 | $18,278 |
| EliquisApixaban | 18 | $17,011 |
| FarxigaDapagliflozin Propanediol | 17 | $15,527 |
| LinzessLinaclotide | 21 | $11,744 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $10,508 |
| Ezetimibe | 13 | $3,039 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $2,870 |
| Gabapentin | 86 | $2,710 |
| Bupropion XlBupropion Hcl | 34 | $2,466 |
| Atorvastatin Calcium | 317 | $2,087 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $192 | $51,66539 claims |
| Novo NordiskOzempic | $419 | $44,73826 claims |
| Lilly USA, LLCMounjaro | $223 | $41,01125 claims |
| AbbVieVraylar, Linzess | $1,888 | $30,02234 claims |
| MerckJanuvia | $46 | $23,98431 claims |
| Johnson & JohnsonXarelto | $12 | $18,49514 claims |
| PfizerEliquis | $417 | $17,01118 claims |
| AstraZenecaFarxiga | $90 | $15,52717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Lincoln
- Allen HuntLincoln$17.2M
- Michael IsraelLincoln$375K
- Randy KohlLincoln$67K
- Matthew GlennLincoln$17K
- Uma NookaLincoln$12K
- Kylie ParshallLincoln$12K
- Michael HuffmanLincoln$11K
- Svjetlana DzikoLincoln$11K
- Eric JohnsonLincoln$10K
- Gary van ErtLincoln$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.